Article
Oncology
Stephanie Durand-Panteix, Jacques Monteil, Magali Sage, Armand Garot, Marie Clavel, Amal Saidi, Julien Torgue, Michel Cogne, Isabelle Quelven
Summary: This study investigated the potential of alpha-RIT in combination with Pb-212-rituximab for NHL treatment using mouse lymphoma cells. Results showed significant tumor regression and increased survival using 277.5 kBq Pb-212-rituximab, highlighting the potency of alpha-RIT for NHL treatment.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Matthew J. Matasar, Marcelo Capra, Muhit Ozcan, Fangfang Lv, Wei Li, Eduardo Yanez, Katya Sapunarova, Tongyu Lin, Jie Jin, Wojciech Jurczak, Aryan Hamed, Ming-Chung Wang, Ross Baker, Igor Bondarenko, Qingyuan Zhang, Jifeng Feng, Klaus Geissler, Mihaela Lazaroiu, Guray Saydam, Arpad Szomor, Krimo Bouabdallah, Rinat Galiulin, Toshiki Uchida, Lidia Mongay Soler, Anjun Cao, Florian Hiemeyer, Aruna Mehra, Barrett H. Childs, Yuankai Shi, Pier Luigi Zinzani
Summary: Copanlisib plus rituximab significantly improved progression-free survival in patients with relapsed indolent non-Hodgkin lymphoma compared with placebo plus rituximab, with the most common grade 3-4 adverse events being hyperglycemia and hypertension.
Article
Oncology
Jennifer A. Foltz, Brian T. Hess, Veronika Bachanova, Nancy L. Bartlett, Melissa M. Berrien-Elliott, Ethan McClain, Michelle Becker-Hapak, Mark Foster, Timothy Schappe, Brad Kahl, Neha Mehta-Shah, Amanda F. Cashen, Nancy D. Marin, Kristen McDaniels, Chaz Moreno, Matthew Mosior, Feng Gao, Obi L. Griffith, Malachi Griffith, Julia A. Wagner, Narendranath Epperla, Amy D. Rock, John Lee, Allegra A. Petti, Patrick Soon-Shiong, Todd A. Fehniger
Summary: The combination therapy of N-803 with rituximab demonstrated safety and durable clinical responses in patients with indolent non-Hodgkin lymphoma, including rituximab-refractory patients. Analysis using CITE-seq revealed altered molecular programs in NK cells and monocytes post-treatment, suggesting the potential for further investigation of N-803 in combination with immunotherapies.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Allison M. Bock, Grzegorz S. Nowakowski, Yucai Wang
Summary: Despite challenges in treating R/R NHL, CD20 x CD3 BsAbs have shown promising efficacy with reduced toxicity. With ongoing expansion and registrational studies, approvals for R/R NHL treatment are expected soon. Further exploration is needed to determine the role of BsAbs in treatment-naive NHL and how to combine them with other therapies, as well as to compare and sequence BsAbs with CAR T-cell therapy.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Article
Oncology
Ningjing Lin, Mingzhi Zhang, Hai Bai, Hui Liu, Jie Cui, Xiaoyan Ke, Huilai Zhang, Lihong Liu, Dongmei Yan, Yongsheng Jiang, Aimin Zang, Junyuan Qi, Li Wang, Zhuogang Liu, Bing Xu, Ying Zhang, Zhihui Zhang, Xielan Zhao, Chunhong Hu, Shenmiao Yang, Hui Zhou, Jinsheng Shi, Zonghong Shao, Ying Xiang, Jiman Zhu, Yuqin Song, Jun Zhu
Summary: GLS-010 (zimberelimab) demonstrates effectiveness and safety in Chinese patients with relapsed or refractory classical Hodgkin lymphoma. The objective response rate assessed by an independent radiology review committee was 90.6%, with a complete response rate of 32.9%. The 12-month progression-free survival and overall survival rates were 78% and 99%, respectively.
EUROPEAN JOURNAL OF CANCER
(2022)
Editorial Material
Hematology
Gita Thanarajasingam, Karin E. Smedby, Ann LaCasce
Summary: This study compared two different treatment approaches for high-risk aggressive B-cell non-Hodgkin lymphoma and confirmed observations and findings regarding lymphoma and its treatment. The long-term follow-up highlighted the importance of studying cumulative and long-term toxicities.
LANCET HAEMATOLOGY
(2021)
Review
Oncology
Stephen Jolles, Sergio Giralt, Tessa Kerre, Hillard M. Lazarus, S. Shahzad Mustafa, Roberto Ria, Donald C. Vinh
Summary: This study conducted a systematic literature review on the potential association between various cancer regimens and infection rates, neutropenia, lymphocytopenia, or hypogammaglobulinemia, which are indicative of secondary immunodeficiency. The results showed that patients with chronic lymphocytic leukemia, multiple myeloma, and non-Hodgkin lymphoma have a high risk of developing secondary immunodeficiency, related infections, and mortality.
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O'Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl
Summary: Loncastuximab tesirine, an antibody-drug conjugate, shows promising efficacy and safety in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, especially for certain specific lymphoma subtypes. This study suggests that loncastuximab tesirine could be a valuable treatment option for these patients and warrants further investigation in phase 2 trials.
Review
Radiology, Nuclear Medicine & Medical Imaging
Francesco Cicone, Giulia Santo, Caroline Bodet-Milin, Giuseppe Lucio Cascini, Francoise Kraeber-Bodere, Caroline Stokke, Arne Kolstad
Summary: Systemic radioimmunotherapy (RIT) is considered the most effective and least toxic treatment for non-Hodgkin lymphoma (NHL). Despite a decrease in the number of patients referred for RIT in western countries, RIT has continued to evolve with the identification of new therapeutic targets, production of new vector molecules, and availability of innovative radionuclides.
SEMINARS IN NUCLEAR MEDICINE
(2023)
Article
Chemistry, Medicinal
Adrian D. Hobson, Jianwen Xu, Christopher C. Marvin, Michael J. McPherson, Markus Hollmann, Michael Gattner, Kristina Dzeyk, Margaret M. Fettis, Agnieszka K. Bischoff, Lu Wang, Julia Fitzgibbons, Lu Wang, Paulin Salomon, Axel Hernandez Jr, Ying Jia, Hetal Sarvaiya, Christian A. Goess, Suzanne L. Mathieu, Ling C. Santora
Summary: To enable subcutaneous dosing, biotherapeutics need to have properties that allow high-concentration formulation and long-term stability in the formulation buffer. The introduction of drug-linkers in ADCs can increase hydrophobicity and aggregation, which are detrimental to subcutaneous dosing properties. This study demonstrates how the physicochemical properties of ADCs can be controlled by the drug-linker chemistry and prodrug chemistry, resulting in significantly improved solution stability. The use of an accelerated stress test in a minimal formulation buffer is crucial for achieving this optimization.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Hematology
Dennis A. Eichenauer, Horst Muller, Leonard Elger, Helen Goergen, Michael Fuchs, Stefanie Kreissl, Boris Boll, Volker Diehl, Bastian von Tresckow, Peter Borchmann, Andreas Engert
Summary: NHL after cHL is a rare event that primarily affects older individuals, with a five-year event-free survival and overall survival estimates of 36.9% and 44.2% respectively.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Oncology
Marie Toukam, Jens Wuerthner, Karin Havenith, Mehdi Hamadani, Paolo F. Caimi, Tim Kopotsha, Hans G. Cruz, Joseph P. Boni
Summary: The purpose of this study was to develop a population pharmacokinetic (PPK) model to characterize the pharmacokinetics of camidanlumab tesirine (Cami) in patients with relapsed/refractory lymphoma. The final model obtained estimates of pharmacokinetic parameters and identified covariates that significantly affect Cami exposure.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2023)
Article
Oncology
Tracy R. Daniels-Wells, Pierre V. Candelaria, Emiko Kranz, Jing Wen, Lan Wang, Masakazu Kamata, Juan C. Almagro, Otoniel Martinez-Maza, Manuel L. Penichet
Summary: Individuals infected with HIV have an increased risk of developing certain cancers, including non-Hodgkin lymphoma. This study demonstrates that antibodies targeting the transferrin receptor 1 (TfR1) can prolong survival in mouse models of AIDS-NHL. Targeting TfR1 with these antibodies may be a potential therapy for AIDS-NHL.
Article
Oncology
Marie Toukam, Joseph P. Boni, Mehdi Hamadani, Paolo F. Caimi, Hans G. Cruz, Jens Wuerthner
Summary: This study investigated the exposure-response relationships of Camidanlumab Tesirine (Cami) using an integrated population pharmacokinetic model. The results showed a significant positive relationship between exposure and overall response rate/overall survival, but this effect was non-significant in the final models due to covariate effects. Higher exposures of Cami were associated with a higher probability of experiencing grade >= 2 adverse events at cycle 6.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2023)
Article
Oncology
Allini Mafra, Mathieu Laversanne, Mary Gospodarowicz, Paulo Klinger, Neimar De Paula Silva, Marion Pineros, Eva Steliarova-Foucher, Freddie Bray, Ariana Znaor
Summary: Global patterns of non-Hodgkin lymphoma (NHL) in 2020 were evaluated using the GLOBOCAN 2020 database. The study found that Eastern Asia, Northern America, and South-Central Asia had the highest number of NHL cases. Incidence rates were higher in men than in women, with the highest rates in Australia, New Zealand, Northern America, Northern Europe, and Western Europe. The highest mortality rates were found in regions in Africa, Western Asia, and Oceania.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Junan Li, Avinash K. Persaud, Jasmine A. Johnson, Dougkas W. Sborov, Mitch A. Phelps, Craig C. Hofmeister, Ming J. Poi
Summary: This study investigated the association of select single nucleotide polymorphisms in the SLC22A3 gene with clinical outcomes in multiple myeloma patients. The results suggested that a specific genotype was associated with altered melphalan transport and an increased risk of severe oral mucositis.
ANTICANCER RESEARCH
(2022)
Article
Hematology
Swagata Goswami, Rajeswaran Mani, Jessica Nunes, Chi-Ling Chiang, Kevan Zapolnik, Eileen Hu, Frank Frissora, Xiaokui Mo, Logan A. Walker, Pearlly Yan, Ralf Bundschuh, Larry Beaver, Raymond Devine, Yo-Ting Tsai, Ann Ventura, Zhiliang Xie, Min Chen, Rosa Lapalombella, Alison Walker, Alice Mims, Karilyn Larkin, Nicole Grieselhuber, Chad Bennett, Mitch Phelps, Erin Hertlein, Gregory Behbehani, Sumithira Vasu, John C. Byrd, Natarajan Muthusamy
Summary: This study reveals that silencing of protein phosphatase 2A (PP2A) directly blocks differentiation in acute myeloid leukemia (AML). Activation of PP2A regulates cell cycle and transcriptional regulators, thereby modulating terminal myeloid differentiation. This finding highlights the potential therapeutic targeting of the PP2A/c-Myc/p21 axis in malignancies with dysregulated maturation fate.
Article
Oncology
Yizhen Guo, Lai Wei, Sandip H. Patel, Gabrielle Lopez, Madison Grogan, Mingjia Li, Tyler Haddad, Andrew Johns, Latha P. Ganesan, Yiping Yang, Daniel J. Spakowicz, Peter G. Shields, Kai He, Erin M. Bertino, Gregory A. Otterson, David P. Carbone, Carolyn Presley, Samuel K. Kulp, Thomas A. Mace, Christopher C. Coss, Mitch A. Phelps, Dwight H. Owen
Summary: Serum albumin and early albumin decrease are significantly associated with overall survival in patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitor (ICI) therapy. This study suggests that albumin changes may serve as potential biomarkers to predict treatment outcomes and warrant further investigation.
CLINICAL LUNG CANCER
(2022)
Article
Plant Sciences
Leslie N. Aldrich, Joanna E. Burdette, Esperanza Carcache de Blanco, Christopher C. Coss, Alessandra S. Eustaquio, James R. Fuchs, A. Douglas Kinghorn, Amanda MacFarlane, Brittney K. Mize, Nicholas H. Oberlies, Jimmy Orjala, Cedric J. Pearce, Mitch A. Phelps, Liva Harinantenaina Rakotondraibe, Yulin Ren, Djaja Doel Soejarto, Brent R. Stockwell, Jack C. Yalowich, Xiaoli Zhang
Summary: Research progress in the discovery of potential anticancer agents from various organisms has been summarized. Lead compounds with structural diversity have been obtained, and potential antitumor activities have been demonstrated. Further investigations are warranted for promising lead compounds.
JOURNAL OF NATURAL PRODUCTS
(2022)
Article
Chemistry, Multidisciplinary
Christopher R. Lucas, Patrick D. Halley, Amjad A. Chowdury, Bonnie K. Harrington, Larry Beaver, Rosa Lapalombella, Amy J. Johnson, Erin K. Hertlein, Mitch A. Phelps, John C. Byrd, Carlos E. Castro
Summary: The study demonstrates that DNA origami (DO) nanotechnology can be used to construct precise nanostructures capable of functionalization and has a wide range of biomedical applications. DO structures distribute well systemically, eliciting a gradually diminishing mild pro-inflammatory response, while being non-toxic.
Article
Biochemistry & Molecular Biology
Justin Thomas, Molly A. Torok, Kriti Agrawal, Timothy Pfau, Trang T. Vu, Justin Lyberger, Hsiaochi Chang, Alyssa Marie M. Castillo, Min Chen, Bryan Remaily, Kyeongmin Kim, Zhiliang Xie, Mary E. Dillhoff, Samuel K. Kulp, Gregory K. Behbehani, Zobeida Cruz-Monserrate, Latha P. Ganesan, Dwight H. Owen, Mitch A. Phelps, Christopher C. Coss, Thomas A. Mace
Summary: The neonatal Fc receptor (FcRn) is responsible for recycling antibodies and albumin in the body. However, little is known about its expression in circulating immune cells. In this study, FcRn expression was found to be elevated in immune cells of pancreatic ductal adenocarcinoma (PDAC) patients and mice with PDAC. These findings may contribute to understanding the mechanisms behind poor efficacy of antibody immunotherapies in PDAC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Editorial Material
Oncology
Swagata Goswami, Chi-Ling Chiang, Kevan Zapolnik, Jessica Nunes, Ann Ventura, Xiaokui Mo, Zhiliang Xie, L. James Lee, Sivasubramanian Baskar, Christoph Rader, John C. Byrd, Mitch Phelps, Bhavana Bhatnagar, Natarajan Muthusamy
Article
Dermatology
Dylan L. Burroughs, Gwendolen Lorch, Yizhen Guo, Kasey Hill, Eric L. Schroeder, Lynette K. Cole, Mitch A. Phelps
Summary: This study aimed to define the noncompartmental pharmacokinetic parameters of intravenous mycophenolate mofetil (MMF) and its downstream metabolites in healthy horses. The results showed that horses biotransform MMF into mycophenolic acid (MPA), MPA phenol glucuronide (MPAG), MPA acyl glucuronide (AcMPAG), and MPA phenol glucoside (MPG).
VETERINARY DERMATOLOGY
(2023)
Meeting Abstract
Hematology
Karen Sweiss, Pritesh Patel, Janet Guo, Kyeongmin Kim, Jordan M. Schecter, Christina Y. Sheng, Dawei Song, Xiaoying Xu, Yaming Su, Weirong Wang, Deepu Madduri, Carolyn C. Jackson, Enrique Zudaire, Tzu-min Yeh, Tito Roccia, Dong Geng, Lida Pacaud, Douglas W. Sborov, Mitch A. Phelps, Craig C. Hofmeister
Article
Oncology
Junan LI, Yu kyoung Cho, Douglas W. Sborov, Mitch A. Phelps, Craig C. Hofmeister, Ming J. Poi
Summary: This study aimed to evaluate the potential impacts of CYP3A4*1B and CYP3A5*3 gene variations on the pharmacokinetic properties of melphalan and clinical outcomes in multiple myeloma patients. The results showed that CYP3A4*1B/*1B and CYP3A5*3/*3 carriers had shorter median progression-free survival time and higher maximum melphalan plasma concentration. Through yet-to-be-identified mechanisms, CYP3A4*1B/*1B and CYP3A5*3/*3 variations might influence melphalan therapy in MM patients.
CANCER GENOMICS & PROTEOMICS
(2023)
Review
Pharmacology & Pharmacy
Kyeongmin Kim, Mitch A. A. Phelps
Summary: Daratumumab is a fully human monoclonal antibody used for the treatment of multiple myeloma and light-chain amyloidosis. It works by targeting CD38 and has demonstrated anti-myeloma activity through various mechanisms. The dosing schedule and exposure to daratumumab are important factors for its efficacy, but disease and patient characteristics do not significantly affect its exposure or response.
CLINICAL PHARMACOKINETICS
(2023)
Article
Oncology
Ryan D. Gentzler, Liza C. Villaruz, John C. Rhee, Bethany Horton, Joseph Mock, Michael Hanley, Kyeongmin Kim, Michelle A. Rudek, Mitch A. Phelps, Michael A. Carducci, Richard Piekarz, Kwon-Sik Park, Timothy N. Bullock, Charles M. Rudin
Summary: This study evaluated the safety of combining the HDAC inhibitor entinostat with standard of care chemotherapy and immunotherapy in patients with small cell lung cancer. The results showed that the addition of entinostat resulted in early onset and severe neutropenia and thrombocytopenia, indicating that further exploration of this combination therapy is not recommended.
Meeting Abstract
Obstetrics & Gynecology
Kara M. Rood, Marwan Ma'ayeh, Mahmoud Abdelwahab, Melanie Paglione, Nicole Abbott, Kasey Hill, Janet Guo, Kyeongmin Kim, Douglas Kniss, Mitch A. Phelps, Maged M. Costantine
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2023)
Meeting Abstract
Obstetrics & Gynecology
Jennifer L. Grasch, Chelsea Cobe, Kristen L. Benninger, Erin M. Cleary, Mitch A. Phelps, Maged M. Costantine, Kara M. Rood
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2023)
Meeting Abstract
Oncology
Ola A. Elgamal, Sandip Vibhute, Sydney Fobare, Abeera Mehmood, Mariah L. Johnson, Jean Truxall, Emily Stahl, Bridget Carmichael, Shelley J. Orwick, Ramasamy Santhanam, Kasey Hill, Susheela Tridandapani, Christopher C. Coss, Alice S. Mims, Karilyn T. Larkin, Mitch A. Phelps, Sharyn D. Baker, Alex Sparreboom, Thomas E. Goodwin, Gerard Hilinski, Chad E. Bennett, Erin Hertlein, John C. Byrd